Most patients on Lilly’s Omvoh® (mirikizumab-mrkz) for Crohn’s disease achieved sustained clinical remission and endoscopic response at two years

More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Nearly 90% of patients who achieved endoscopic response at one year sustained it at two years Omvoh is the first IL-23p19 antagonist to demonstrate…